Investor Relations

Thank you for checking on Entheon. We are glad to have you here!

"Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada."

- Timothy Ko, CEO

Press Releases

Official publications released at Newsfile Corp.

Stock information

CSE:ENBI

OTC:ENTBF

FSE:1XU1

Get in touch

Please enter your information to receive our investor package or reach out to us directly using the information below.

Joseph Cullen
Investor Relations

ir@entheonbiomedical.com
+1 (778) 919-8615

Please remember our office hours are in Pacific Time (GMT-8, Vancouver - BC, Canada)
By submitting this form you agree to receive communications from Entheon Biomedical. We commit to never selling your data and to keep your information safe. Read our Privacy Policy.
Thank you!
We will get in touch soon.
Oops! Something went wrong while submitting the form.